3月9日，在港股整体承压市况下，科济药业-B（02171.HK）的股价却逆势上扬，走出了一波强劲的大涨行情，盘中一度爆拉42.59%，截至收盘，涨幅为28.06%，报13.92港元/股。股价逆势上扬的背后，离不开两大核心利好消息的支撑。首先，3月9日，科济药业公告称，公司将纳入港股通证券名单中，本次调整自2026年3月9日起正式生效。科济药业表示，本次纳入体现了市场对公司核心CAR-T业务发展潜力...
Source Link3月9日，在港股整体承压市况下，科济药业-B（02171.HK）的股价却逆势上扬，走出了一波强劲的大涨行情，盘中一度爆拉42.59%，截至收盘，涨幅为28.06%，报13.92港元/股。股价逆势上扬的背后，离不开两大核心利好消息的支撑。首先，3月9日，科济药业公告称，公司将纳入港股通证券名单中，本次调整自2026年3月9日起正式生效。科济药业表示，本次纳入体现了市场对公司核心CAR-T业务发展潜力...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.